

IN THE CLAIMS

Please amend the claims as follows:

Claims 1-9 (Canceled).

Claim 10 (Currently Amended): A method for treatment of a Central Nervous System (CNS) disease, comprising administering₁ to a ~~patient~~ subject suffering from a disease of the CNS₁, a conjugate comprising an active substance in an amount sufficient to treat ~~for treatment of said~~ disease of the CNS₁, wherein the active substance is coupled directly or indirectly by a covalent bond to one of the following peptides: SynB1 (SEQ ID NO: 11) or SynB3 (SEQ ID NO: 12)[[;]] ~~and treating said disease of the CNS~~, and wherein said active substance is an active chemical ~~molecules~~ molecule, and ~~wherein~~ said disease of the CNS is selected from the group consisting of brain cancer, pain and meningitis.

Claim 11 (Currently Amended): A method for driving a substance across the Blood Brain Barrier (BBB) to the Central Nervous System (CNS), comprising:

preparing a conjugate comprising an active substance coupled directly or indirectly by a covalent bond to one of the following peptides: SynB1 (SEQ ID NO: 11) or SynB3 (SEQ ID NO: 12), wherein said active substance is an active chemical ~~molecules~~ molecule in the treatment of the CNS;

administering said conjugate to a ~~patient~~ subject suffering from a disease of the CNS in an amount sufficient to drive said active substance across the BBB to the CNS; and

driving ~~one of the following peptides: SynB1 (SEQ ID NO: 11) or SynB3 (SEQ ID NO: 12)~~ said active substance across the BBB to the CNS₁,

wherein said disease of the CNS is selected from the group consisting of brain cancer, pain, and meningitis.

Claim 12 (Previously Presented): The method of claim 10, wherein said active chemical molecule is selected from the group consisting of antitumoral agents, antibiotic agents and analgesic agents.

Claim 13 (Previously Presented): The method of claim 11, wherein said active chemical molecule is selected from the group consisting of antitumoral agents, antibiotic agents and analgesic agents.

Claim 14 (New): The method of claim 10, wherein the amount of said conjugate administered to the subject is from 0.16 to 2.5 mg/kg of body weight.

Claim 15 (New): The method of claim 11, wherein the amount of said conjugate administered to the subject is from 0.3 to 3 mg/kg of body weight.